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Early identification and treatment are associated with improved outcomes in bipolar
disorder (BPD) and schizophrenia (SCZ). Screening for the presence of these disorders
usually involves time-intensive interviews that may not be practical in settings where
mental health providers are limited. Thus, individuals at earlier stages of illness are
often not identified. The Washington Early Recognition Center Affectivity and Psychosis
(WERCAP) screen is a self-report questionnaire originally developed to identify clinical
risk for developing bipolar or psychotic disorders. The goal of the current study was to
investigate the utility of the WERCAP Screen and two complementary questionnaires,
the WERC Stress Screen and the WERC Substance Screen, in identifying individuals with
established SCZ or BPD. Participants consisted of 35 BPD and 34 SCZ patients, as well
as 32 controls (CON), aged 18–30 years. Univariate analyses were used to test for score
differences between groups. Logistic regression and receiver operating characteristic
(ROC) curves were used to identify diagnostic predictors. Significant group differences
were found for the psychosis section of the WERCAP (pWERCAP; p < 0.001), affective
section of the WERCAP (aWERCAP; p = 0.001), and stress severity (p = 0.027). No
significant group differences were found in the rates of substance use as measured by
the WERC Substance Screen (p = 0.267). Only the aWERCAP and pWERCAP scores
were useful predictors of diagnostic category. ROC curve analysis showed the optimal
cut point on the aWERCAP to identify BPD among our participant groups was a score
of >20 [area under the curve (AUC): 0.87; sensitivity: 0.91; specificity: 0.71], while that
for the pWERCAP to identify SCZ was a score of >13 (AUC: 0.89; sensitivity: 0.88;
specificity: 0.82). These results indicate that the WERCAP Screen may be useful in
screening individuals for BPD and SCZ and that identifying stress and substance-use
severity can be rapidly done using self-report questionnaires. Larger studies in undiagnosed individuals will be needed to test the WERCAP Screen’s ability to identify mania
or psychosis in the community.
Keywords: bipolar disorder, schizophrenia, WERCAP, psychosis, stress, questionnaire
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INTRODUCTION

individuals with established bipolar or psychotic disorder diagnoses and also inform on illness severity.
Stress (23) and substance use (24) are both associated with
risk of psychosis and decompensation in those with psychotic
or BPDs; thus, reliably assessing their severities could provide
valuable information for clinicians. A number of substances
have been found to be associated with risk of psychosis and BPD,
most commonly tobacco (25, 26) and cannabis (27). There is
now strong evidence suggesting that cannabis use can trigger the
onset of psychosis (28–30). Progression to greater cannabis usage
frequency is associated with greater risk of psychosis (31). Higher
rates of cannabis use have been consistently linked with earlier
age of onset in psychosis (30, 32–35) with some studies reporting
a similar association in BPD (36–38).
Substance use has also been reported to exacerbate symptoms
in patients that have already been diagnosed with SCZ and BPD.
SCZ patients with a history of cannabis use tend to have longer
hospital stays and more frequent readmissions compared to cannabis non-users (39). Cannabis use is also linked with an increase
in psychotic (40–43) and manic symptoms (44). Cannabis use
is associated with worse treatment outcomes and functioning in
patients with psychosis (45–47) and BPD (48, 49). Some studies
have also found tobacco use to be associated with greater illness
severity (50). Tobacco smoking is highly prevalent among SCZ
and bipolar patients (51) and has been associated with worse
outcomes and lower remission rates in BPD (49, 52). In addition, there have been case reports of psychiatric relapse following
excessive caffeine consumption in patients suffering from SCZ
(53) and BPD (54).
Psychosocial stress is another risk factor shared between SCZ
and BPD, along with other psychiatric disorders (55, 56). There is
extensive evidence linking early childhood trauma with increased
risk of psychosis (57–59) and BPD (60). It has been hypothesized
that childhood adversity results in increased vulnerability to
stress and psychiatric disorder (61). SCZ, BPD, and depression
patients all tend to report increased sensitivity to stress (62).
Moreover, greater exposure to childhood adversity has been
correlated with higher levels of perceived stress and increased
psychopathology (63). Stressors later in life have also been
found to increase the risk of psychotic (64) and manic (65–67)
episodes. More recent studies have reported everyday stressors
in adult life to be correlated with an increase in psychotic (68)
and manic (69) symptoms. Thus, assessing stress severity could
conceivably improve the identification of individuals at risk for
psychosis and BPD.
We have previously developed tools to capture psychosocial stress load and substance-use habits. The WERC Stress
Screen (hereafter referred to as “Stress Screen”) is a self-report
questionnaire that assesses the overall stress burden currently
experienced by the individual, and also quantifies the individual
contributions of common psychosocial stressors to the total
stress burden (22). The WERC Substance Screen (hereafter
referred to as “Substance Screen”) allows respondents to selfreport on the usage frequencies of multiple substances that may
influence brain function.
The current study explores the utility of our quantitative
screening instruments in a sample of patients with SCZ and

Schizophrenia (SCZ) and bipolar disorder (BPD) are complex
mental illnesses with onset in adolescence and are among the
leading causes of disability worldwide (1). Early identification and
initiation of antipsychotic therapy are associated with improved
prognoses in SCZ, whereas longer durations of untreated illness
are associated with worse outcomes (2, 3). This holds true across
different nations and cultures (4, 5). Similarly, in BPD, delayed
diagnosis and treatment are associated with more hospitalizations, increased suicidality (6), and impaired social function (7).
Patients with recurrent depressive episodes in BPD may be misdiagnosed with unipolar depression, leading to a longer duration of
untreated illness and worse outcomes (8–10). Misdiagnosis and
inappropriate treatment with antidepressants can increase mania
and exacerbation of the episode (11). In some practices, it takes an
average of about 10 years between the onset of BPD and initiation
of treatment with mood stabilizers (12). The challenges involved
in early recognition and treatment of SCZ and BPD support the
need for a reliable screening instrument.
Bipolar disorder and SCZ are typically diagnosed by a clinician
or by structured clinical interviews, which are time consuming
and, therefore, not practical for screening purposes. Commonly
used screening questionnaires in BPD, such as the Altman SelfRating Mania Scale (13), Young Mania Rating Scale (14), or the
Bipolar Spectrum Diagnostic Scale (BSDS) (15), either probe for
severity of current manic-like symptoms or generate unacceptably
high rates of false positives and low sensitivity (16). For example,
the Mood Disorders Questionnaire, the most extensively studied
of instruments for detecting BPD, was found to have a positive
predictive value (PPV) of 22.1% (17). Likewise, the BSDS has a
PPV of only 16% (18). Thus, the need for a rapid and reliable
means to screen for BPD remains unmet. Similarly, the community assessment of psychic experiences (CAPE)-42, a screening
instrument for detecting psychosis, has a PPV of only 23.5% (19).
Other rating instruments commonly used in assessing SCZ or
other psychotic disorders, such as the Scale for the Assessment of
Positive Symptoms (20) or the Positive and Negative Syndrome
Scale (21), probe for current psychotic symptoms and are not
designed to assist in diagnosis.
The Washington Early Recognition Center Affectivity and
Psychosis (WERCAP) screen was developed to accurately and
efficiently identify individuals at risk of bipolar and psychotic
disorders. The WERCAP Screen is a quantitative measure of
affective and psychotic symptoms that elicits information about
symptom frequency and the degree of resulting dysfunction
(“functionality”). The WERCAP Screen has been validated in a
non-clinical youth population in the US, provides results comparable to the structured interview for prodromal syndromes
(SIPS) in a much shorter period of time, and is designed to be
cross-culturally applicable (22). The WERCAP Screen has two
sections, the aWERCAP and pWERCAP, which measure the risk
of developing BPD (“affectivity”) and psychosis, respectively.
Unlike other screening instruments, the WERCAP Screen was
designed to assess chronic or lifetime affective or psychotic
symptoms (although a time interval can be specified for more
acute symptoms). Thus, it could potentially be used to identify
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BPD. Our objective was to determine whether the WERCAP
Screen, Stress Screen, or Substance Screen could predict diagnosis in a clinical population and the optimal cutoff thresholds
on these instruments. We hypothesized that the measures of
psychosis and affectivity would be the most useful predictors
of diagnosis.

precedence given to the psychiatrist’s determination. Exclusion
criteria during initial screening included (1) a history of substance
dependence or substance abuse during the 6 months prior to
participation, (2) a currently unstable clinical disorder or severe
general medical disorder, or (3) a history of head injury, multiple
seizures, or concussions resulting in unconsciousness for more
than 30 min. Table 1 presents demographic information for the
three participant groups.

MATERIALS AND METHODS

WERC Screening Forms

The Institutional Review Board of Washington University Medical
School in St. Louis approved all procedures and study materials.
All participants in the study provided informed consent.

Participants completed three screening forms: the WERCAP
Screen, the Stress Screen (22), and the Substance Screen. These
forms are available for public use (http://werc.wustl.edu/home/
screeninginstruments).
The WERCAP Screen assesses risk of BPD and psychosis
based on a quantification of lifetime symptom burden. The
WERCAP Screen consists of a total of 16 questions, the first
half of which are designed to assess affective symptoms experienced by individuals, while the remaining questions assess risk
of psychosis. The majority of questions (10 out of 16) require
two responses, including a rating of the frequency of symptom
occurrence, and if present, the severity of the associated functional impairment. For the item probing into decreased need
for sleep, respondents were asked to rate symptom duration
rather than degree of functional impairment. Six questions in
the affectivity section assess only symptom frequency, since they

Participants

One hundred two individuals ages 18–30 years participated in the
study, which consisted of three groups: BPD (BPD, n = 35), SCZ
(SCZ, n = 34), and healthy controls (CON, n = 32). Participants
were recruited using a combination of flyers posted in public
locations, recruitment information posted to university websites,
as well as clinic referrals. Consequently, our sample size was
limited by clinical availability of individuals with SCZ and BPD
who met inclusion criteria. Diagnosis was determined based
on the agreement of assessments by a research psychiatrist and
a trained research assistant using the structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured
clinical interview for DSM-IV axis II disorders (SCID-II), with
TABLE 1 | Demographics for each diagnostic group.
Control (N = 32)

Bipolar (N = 35)

Schizophrenia (N = 34)

Total (N = 101)

Mean age (SD)

24.1 (3.03)

25.1 (3.48)

25.8 (3.44)

25.0 (3.37)

Characteristic

N (%)

N (%)

Gender
Female
Male

20 (62.5)
12 (37.5)

25 (71.4)
10 (28.6)

7 (20.6)
27 (79.4)

52 (52.5)
49 (48.5)

Ethnicity
American Indian/Alaskan native
Asian
Black/African-American
Native Hawaiian/Pacific Islander
White
Biracial/Multiracial
Other/unknown

0 (0.0)
3 (9.4)
11 (34.0)
0 (0.0)
17 (53.1)
1 (3.1)
0 (0.0)

0 (0.0)
3 (8.6)
7 (20.0)
0 (0.0)
24 (68.6)
1 (2.9)
0 (0.0)

0 (0.0)
0 (0.0)
21 (62.4)
0 (0.0)
11 (31.4)
1 (2.9)
1 (2.9)

0 (0.0)
6 (5.9)
39 (38.6)
0 (0.0)
52 (51.0)
3 (3.0)
1 (1.0)

Employment
Full time
Part time
Unemployed
Full-time student
Part-time student
Other

15 (46.9)
6 (18.8)
2 (6.3)
6 (18.8)
3 (9.4)
0 (0.0)

12 (34.3)
6 (17.1)
8 (22.9)
5 (14.3)
3 (8.6)
1 (2.9)

1 (2.9)
7 (20.0)
21 (61.8)
4 (11.4)
0 (0.0)
0 (0.0)

28 (27.7)
19 (18.8)
31 (30.7)
15 (14.9)
6 (5.9)
1 (1.0)

Level of education
Graduate professional training
College/university graduate
Partial college
High school graduate
Partial high school
Junior high school
Less than 7 years of school
Unknown

5 (15.6)
10 (31.3)
14 (43.8)
0 (0.0)
3 (9.4)
0 (0.0)
0 (0.0)
0 (0.0)

4 (11.4)
7 (20.0)
18 (51.4)
5 (14.3)
1 (2.9)
0 (0.0)
0 (0.0)
0 (0.0)

0 (0.0)
1 (2.9)
15 (44.1)
13 (38.2)
3 (8.8)
1 (2.9)
0 (0.0)
0 (0.0)

9 (8.9)
18 (17.8)
47 (46.5)
18 (17.8)
7 (6.9)
1 (1.0)
0 (0.0)
0 (0.0)
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inquire about symptoms that do not typically impair function,
or the degree of resulting dysfunction is difficult to assess. The
responses were converted into numerical values as follows:
No = 0, Once = 1, Rarely (<yearly) = 2, Sometimes (>yearly–
monthly) = 3, Often (>monthly–weekly) = 4, and Almost Always
(>weekly–daily) = 5. For items assessing effect on functionality,
responses were converted as follows: Not at All = 0, A Little = 1,
Moderately = 2, Severely = 3. The frequency and functionality scores for items 1–8 were summed to generate a composite
aWERCAP (affectivity) score, and the remaining items (9–16)
were summed to generate the composite pWERCAP (psychosis)
score. The maximum aWERCAP score possible is 49, and the
maximum pWERCAP score is 64, yielding a maximum total
WERCAP Screen score of 113.
The Stress Screen assesses the total stress burden of 23 common psychosocial stressors, such as one’s relationships with
family and friends, substance use, or the workplace [see Ref.
(22) for a complete list]. Space is also provided to write in up to
two additional stressors. By default, the Stress Screen is designed
to capture the current stress load on an individual. Respondents
are asked to rate the extent to which they are affected by each
stressor by marking the appropriate checkbox. Each response
is converted to a numerical rating (No = 0, A Little = 1,
Moderate = 2, A Lot = 5, Severely = 10), and then summed to
generate the Stress Screen score. The maximum Stress Screen
score possible is 230.
The Substance Screen is a 20-item questionnaire that assesses
the current substance-use habits of the respondent. Respondents
were asked to rate their usage frequency of a variety of psychotropic substances, such as caffeine, nicotine, prescription drugs,
etc. [see Ref. (22) for a complete list] and could also choose to
write in up to two additional substances. The frequency responses
were converted into a numerical score using the same scale as
that in the WERCAP Screen, and then summed to generate the
Substance Screen score.

(ROC) curves were generated for aWERCAP and pWERCAP to
study classification with varying thresholds and determine the
thresholds with optimum sensitivity and specificity. Substance
and Stress Screen scores were not predictive of diagnostic group
membership in the logistic regressions and, therefore, were not
considered for this analysis.

RESULTS
Demographics

Demographic information for each diagnostic group is presented
in Table 1. Mean age was not significantly different between
groups (F(2,98) = 1.848, p = 0.163). However, there were significant differences in gender (χ2 = 20.122, p < 0.001) and ethnicity
(χ2 = 17.465, p = 0.026) between groups. Psychiatric comorbidities in each group are shown in Table 2.

WERCAP Screen

Univariate analyses showed significant group effects for
aWERCAP (F(2,92) = 52.904, p < 0.001) and pWERCAP
(F(2,92) = 50.378, p < 0.001, η2 = 0.523), but not for stress
or substance scores. The relationship between individual
aWERCAP, pWERCAP, and Stress Screen scores is depicted
in Figure 1. Average scores for each of the screens are shown in
Table 3. Pairwise comparisons between diagnoses, Bonferroni
correcting for multiple comparisons, showed that BPD had
significantly higher aWERCAP scores than CON (p < 0.001)
and SCZ (p = 0.001). Scores on the aWERCAP in SCZ were
also higher than in CON (p < 0.001). pWERCAP scores were
significantly higher in SCZ compared to BPD (p < 0.001)
and CON (p < 0.001), as well as in BPD compared to CON
(p = 0.001). Mean aWERCAP scores did not significantly differ
between genders (t = 0.691, p = 0.491). Mean aWERCAP item
scores broken down by sex and diagnosis are shown in Figure 2.
Males experienced significantly higher total psychotic symptom
scores than females (t = −2.324, p = 0.022). Mean pWERCAP
item scores for males and females in each diagnostic group are
shown in Figure 3.

Data Analysis

Statistical analyses were performed using IBM’s SPSS software
(IBM SPSS Statistics for Macintosh, Version 24.0, Armonk, NY,
USA). Demographic differences between diagnostic groups
were assessed with one-way ANOVAs treating diagnosis as a
fixed factor or chi-square (χ2) tests as appropriate. Betweengroup differences in aWERCAP, pWERCAP, and Stress Screen
scores were examined using univariate analysis of covariance
(ANCOVA) tests, including gender, age, and years of education
as covariates, followed by post hoc pairwise tests, corrected for
multiple comparisons treating diagnostic group as a fixed effect.
We utilized logistic regression to examine the capability of
the aWERCAP, pWERCAP, WERC Stress Screen, and number
of substances used to predict diagnostic group. The number of
substances measured by the Substance Screen was used in the
logistic regression instead of a Substance Screen score derived
from summing all substance usage frequencies, due to substantial
potency variability of the different substances. Only the most
prevalent substances used by our participants were included in
the logistic regression (i.e., tobacco, coffee, other caffeinated beverages, alcohol, and cannabis). Receiver Operating Characteristic
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Stress Screen

Univariate analysis of Stress Screen scores showed a significant
main effect of diagnostic group (F(2,92) = 3.740, p = 0.027). Mean
Stress Screen item scores for each diagnostic group are shown in
Figure 4. Pairwise comparisons showed that BPD had significantly
higher Stress Screen scores than the CON (p = 0.033). However,
BPD did not significantly differ from the SCZ on stress severity.
SCZ did not significantly differ from CON on stress severity
(p = 0.182). We found no significant differences in WERC Stress
scores across genders (t = 0.541, p = 0.589).

Substance Screen

A comparison of the rate of substance use showed only a marginal
effect of diagnosis (F(2,92) = 2.987, p = 0.055). BPD reported using
significantly more substances than CON (p = 0.015) or SCZ
(p = 0.032). There was no significant difference in the number
of substances used between the CON and SCZ. SCZ reported
tobacco use at significantly higher rates than CON (p = 0.021).
4
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TABLE 2 | Prevalence of psychiatric disorders for each diagnostic group (N = 101).

Psychiatric diagnosis
No diagnosis
Mood disorders
Major depressive disorder
Bipolar disorder
Anxiety disorders
Generalized anxiety disorder
Panic disorder
Panic disorder w/agoraphobia
Agoraphobia w/o panic disorder
PTSD
Social phobia
Specific phobia
Obsessive compulsive disorders
Obsessive compulsive disorder
Body dysmorphic disorder
Personality disorders
Borderline PD
Avoidant PD
Schizotypal PD
Obsessive compulsive PD
Antisocial PD
Dependent PD
Paranoid PD
Narcissistic PD
Psychotic disorders
Schizoaffective disorder
Schizophrenia
Psychosis NOS
Substance-related disorders
Cannabis abuse
Cannabis dependence
Alcohol abuse
Alcohol dependence
Opioid dependence
Polysubstance abuse
Hallucinogen dependence
Stimulant dependence
Eating disorders
Bulimia nervosa
Binge eating disorder

Control (N = 32)

Bipolar (N = 35)

Schizophrenia (N = 34)

Total (N = 101)

N (%)

N (%)

N (%)

N (%)

30 (93.8)
2 (6.25)
2 (6.25)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

1 (2.9)
33 (94.3)
0 (0)
33 (94.3)
30 (85.7)
3 (8.6)
2 (5.7)
0 (0)
4 (11.4)
7 (20.0)
10 (28.6)
4 (11.4)
0 (0)
0 (0)
0 (0)
22 (62.9)
5 (14.3)
8 (22.9)
0 (0)
5 (14.3)
1 (2.9)
3 (8.6)
5 (14.3)
3 (8.6)
1 (2.9)
1 (2.9)
0 (0)
0 (0)
0 (0)
1 (2.9)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
2 (5.7)
1 (2.9)
1 (2.9)

31 (30.7)
35 (34.7)
2 (2.0)
33 (32.7)
49 (48.5)
8 (7.9)
3 (3.0)
3 (3.0)
9 (8.9)
11 (10.9)
12 (11.9)
6 (5.9)
1 (1.0)
1 (1.0)
4 (4.0)
31 (30.7)
7 (6.9)
12 (11.9)
1 (1.0)
6 (5.9)
1 (1.0)
4 (4.0)
9 (8.9)
4 (4.0)
35 (34.7)
5 (5.0)
29 (28.7)
1 (1.0)
2 (2.0)
3 (3.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
2 (2.0)
1 (1.0)
1 (1.0)

BPD (p < 0.001), and only the pWERCAP score significantly
predicted SCZ (p = 0.001). Results of the logistic regression are
presented in Table 4.

BPD had significantly higher coffee consumption rates than
SCZ (p = 0.02). We found no significant differences in the rates
of substance use as measured by the WERC Substance Screen
(t = 1.117, p = 0.267).

ROC Curves for WERCAP

Logistic Regression – Predicting
Diagnostic Group

To evaluate the discriminative power of the WERCAP screen to
detect BPD and SCZ, ROC curves were calculated for aWERCAP
and pWERCAP (see Figure 5). For detecting BPD, aWERCAP
performed significantly better than chance, with an area under the
curve (AUC) of 0.873 (p < 0.001); however, pWERCAP was not
significantly better than chance at detecting BPD (AUC = 0.524,
p = 0.695). The optimal cutoff on the aWERCAP to identify
BPD was 20 (Table 5). At this cut point, sensitivity was 0.91 and
specificity was 0.71.
For detecting SCZ, pWERCAP demonstrated an AUC of 0.894
(p < 0.001), indicating that pWERCAP has very good discrimination for SCZ. aWERCAP was not significantly better than chance

Overall, logistic regression models using the aWERCAP, pWERCAP, Stress Screen, and number of substances used as predictors
correctly predicted diagnosis in 89.1% of participants. Specifically,
the model correctly predicted 93.8% of CON, 85.7% of BPD,
and 88.2% of SCZ. However, only the aWERCAP (χ2 = 47.835,
p < 0.001) and pWERCAP (χ2 = 79.974, p < 0.001) scores were
useful predictors of diagnostic category, whereas the Stress
Screen (χ2 = 2.587, p = 0.274) and number of substances used
(χ2 = 2.918, p = 0.232) did not significantly contribute to group
prediction. Only the aWERCAP score significantly predicted

Frontiers in Psychiatry | www.frontiersin.org

0 (0)
0 (0)
0 (0)
0 (0)
19 (55.9)
5 (14.7)
1 (2.9)
3 (8.8)
5 (14.7)
4 (11.8)
2 (5.9)
2 (5.9)
1 (2.9)
1 (2.9)
0 (0)
9 (26.5)
2 (5.9)
4 (11.8)
1 (2.9)
1 (2.9)
0 (0)
1 (2.9)
4 (11.8)
1 (2.9)
34 (100.0)
4 (11.8)
29 (85.3)
1 (2.9)
2 (5.9)
2 (5.9)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
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FIGURE 1 | 3D scatter-plot showing Stress Screen scores, aWERCAP composite scores, and pWERCAP composite scores in each diagnostic group.

BPD scored significantly higher on the affective symptoms
(aWERCAP) than the control or SCZ groups. The SCZ group,
however, had higher affective symptoms than controls, consistent with the increased affective symptoms (primarily depressive
symptoms) often seen in SCZ patients (70–76). Both of our
patient groups also had higher psychotic symptoms (pWERCAP)
than the control group, with the SCZ patients having the most
severe symptoms. The BPD group, however, reported the most
significant psychosocial stress severity, as well as the most substances used. This is consistent with results from previous studies
showing BPD with a higher prevalence of substance-use disorders
(SUDs) than any other psychiatric disorder (77). A high Stress
Screen score may not necessarily indicate greater stress reactivity
to everyday stressors. Higher sensitivity to stress has been associated with psychosis risk (78–80) and also has been reported in
SCZ (81) as well as BPD (82). In addition, several reports have
associated childhood adversity with risk of psychosis (58, 83),
suggesting the importance of documenting lifetime stressors.
Abnormalities in the hypothalamic–pituitary–adrenal axis, a key
mediator of the stress response, have been implicated in both SCZ
(84) and BPD (85, 86). Stress hypersensitivity and psychosocial
stress increase susceptibility to SCZ (87, 88) and BPD (89, 90)

TABLE 3 | Mean (SD) WERC Screen scores and number of substances
used in each diagnostic category.

Stress Screen
Number of substances
aWERCAP
pWERCAP

Control

Bipolar

Schizophrenia

24 (34)
3.3 (0.4)
7.1 (8.1)
0.8 (3.1)

46 (37)
4.7 (0.4)
29.2 (7.8)
13.2 (12.3)

39 (28)
3.4 (0.4)
19.0 (11.0)
31.8 (16.8)

at detecting SCZ (AUC = 0.504, p = 0.951). The optimal cutoff
on the pWERCAP to identify SCZ in this study population was
13 (Table 5). At this cut point, sensitivity was 0.88 and specificity
was 0.82.

DISCUSSION
A goal of this study was to test whether the WERC questionnaires
could reliably identify participants with BPD and SCZ. We first
investigated performance on these questionnaires by participants
with these diagnoses and controls. There was a significant main
effect of diagnosis for WERCAP scores, stress severity, and the
number of substances used. As we predicted, individuals with

Frontiers in Psychiatry | www.frontiersin.org
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FIGURE 2 | Mean aWERCAP Screen individual item scores (frequency) in males vs. females of each diagnostic group, with standard error bars.
x-axis = individual aWERCAP items, y-axis = mean aWERCAP frequency score, derived by summing and averaging the frequency responses in the affectivity section.

FIGURE 3 | Mean pWERCAP Screen individual item scores (frequency) in males vs. females of each diagnostic group, with standard error bars.
x-axis = individual pWERCAP items, y-axis = mean pWERCAP frequency score, derived by summing and averaging the frequency responses in the psychosis section.

and also exacerbate symptoms in both disorders (91). Index
manic (69) and psychotic (92) episodes are often preceded by an
increase in stressful life events. Thus, the WERCAP Stress Screen
may be a useful tool for schools and clinics in monitoring at-risk
individuals to prevent onset or relapse.
The affectivity (aWERCAP) score alone identified individuals with BPD in our sample with high sensitivity and specificity,
suggesting that the aWERCAP may be useful for detecting BPD
in larger settings. Our current findings indicated a minimum
aWERCAP cutoff score of 20 for detection of BPD diagnosis,
below which an individual would be unlikely to have this
diagnosis. Higher scores, however, do not necessarily imply
a diagnosis of BPD, as there are likely other conditions that
could be associated with severe affective symptoms. While not
addressed in the current study, it is plausible, for example,

Frontiers in Psychiatry | www.frontiersin.org

that individuals with certain personality disorders that involve
mood lability, such as borderline personality disorder, may
report high aWERCAP scores. Depressive disorders may
also sometimes be associated with mood lability or irritability, although the majority of the aWERCAP question items
would be unlikely to be endorsed by affected individuals. It is,
therefore, expected that the aWERCAP alone would result in
high false positive rates for BPD in community surveys, and
would be insufficient to identify affected individuals. However,
the aWERCAP may be suitable as an initial screening tool
that would identify individuals who may require clinical or
structured assessments.
For the pWERCAP, a cutoff score of 13 was associated with 88%
sensitivity, 82% specificity, 83% PPV, and 87% negative predictive
value for SCZ diagnosis in our study sample. This score seemed
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FIGURE 4 | Mean WERCAP Stress Screen individual item scores in each diagnostic group, with standard error bars. x-axis = individual Stress Screen
items, y-axis = mean Stress Screen scores for each item.
TABLE 4 | Logistic regression analysis of WERC Screens for diagnosis, with control or schizophrenia group as reference category.
β

Predictor

SE β

Wald’s χ2

df

p

eβ (odds ratio)

Bipolar disordera
Constant
aWERCAP
pWERCAP
WERC stress
Substances used

−6.446
0.279
0.282
−0.028
0.343

1.721
0.078
0.165
0.018
0.222

14.033
12.956
2.915
2.241
2.390

1
1
1
1
1

<0.001
<0.001
0.134
0.973
0.122

1.322
1.326
0.973
1.409

Schizophreniaa
Constant
aWERCAP
pWERCAP
WERC stress
Substances used

−2.310
−0.074
0.520
−0.020
0.107

1.210
0.083
0.170
0.020
0.281

3.647
0.802
9.358
1.038
0.146

1
1
1
1
1

0.056
0.370
0.002
0.308
0.702

0.928
1.682
0.980
1.113

Bipolar disorderb
Constant
aWERCAP
pWERCAP
WERC stress
Substances used

−4.136
0.353
−0.237
−0.007
0.236

1.683
0.096
0.063
0.013
0.246

6.042
13.521
14.073
0.297
0.914

1
1
1
1
1

0.014
<0.001
<0.001
0.583
339

1.424
0.789
0.993
1.266

χ2

df

p

Test
Overall model evaluation
Likelihood ratio test
Goodness-of-fit test
Pearson

156.555

8

<0.001

153.307

190

0.976

Results of multinomial logistic regression predicting diagnosis. Cox and Snell R2 = 0.78, Nagelkerke R2 = 0.886, McFadden R2 = 0.706. Healthy controls were treated as the
reference group in the above analysis.
b
Schizophrenia was treated as the reference category in the above analysis for comparison against the bipolar group.
a

low, considering that in our previous study (22), a score of >30
was found to best correlate with risk for developing a psychotic
disorder using a gold standard of psychosis-risk assessment.
Frontiers in Psychiatry | www.frontiersin.org

Thus, a higher score would be expected in SCZ patients. One
explanation for this discrepancy is that our study population was
largely medicated and stable and, therefore, would exhibit milder
8
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FIGURE 5 | WERCAP Screen receiver operating characteristic (ROC) curve and area under the curve (AUC) for detecting (A) bipolar disorder and (B)
schizophrenia.
TABLE 5 | ROC curve analysis for WERCAP and diagnosis.
Cutoff

0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
19
20
21
22
23
25
26
30
35
40
45

Sensitivity

Specificity

aWERCAP

pWERCAP

100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
97.00
94.00
94.00
91.00
91.00
91.00
86.00
80.00
77.00
77.00
66.00
40.00
17.00
11.00
0.00

100.00
94.00
94.00
94.00
94.00
94.00
94.00
94.00
91.00
91.00
91.00
91.00
88.00
88.00
82.00
79.00
79.00
79.00
76.00
74.00
68.00
65.00
62.00
59.00
59.00
53.00
44.00
35.00
18.00

aWERCAP
0.00
14.00
15.00
24.00
29.00
36.00
41.00
42.00
45.00
47.00
47.00
48.00
55.00
56.00
61.00
61.00
61.00
64.00
67.00
71.00
71.00
71.00
73.00
85.00
89.00
91.00
97.00
100.00
100.00

PPV

pWERCAP
0.00
51.00
51.00
51.00
55.00
60.00
64.00
69.00
73.00
73.00
75.00
76.00
82.00
82.00
84.00
87.00
87.00
88.00
90.00
90.00
90.0
90.0
90.0
93.00
94.00
97.00
97.00
99.00
99.00

aWERCAP
50.0
54.0
54.0
57.0
58.0
61.0
63.0
63.0
65.0
65.0
65.0
66.0
69.0
69.0
71.0
71.0
71.0
72.0
73.0
76.0
75.0
73.0
74.0
84.0
86.0
82.0
85.0
100.0
n/a

NPV
pWERCAP

aWERCAP

50.0
65.7
65.7
65.7
67.6
70.1
72.3
75.2
77.1
77.1
78.4
79.1
83.0
83.0
83.7
85.9
87.0
88.0
88.4
88.1
87.0
87.0
86.0
89.4
91.0
94.6
93.6
97.2
94.7

n/a
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
100.0
95.0
91.0
91.0
88.0
88.0
89.0
84.0
78.0
76.0
79.0
72.0
60.0
54.0
53.0
50.0

pWERCAP
n/a
89.5
89.5
89.5
90.2
90.9
91.4
92.0
89.0
89.0
89.3
89.4
87.2
87.2
82.4
80.6
81.0
81.00
78.9
77.6
74.0
72.0
70.0
69.4
70.0
67.4
63.4
60.4
54.7

Values shown reflect the aWERCAP’s predictive capability of bipolar disorder and the pWERCAP’s ability to predict schizophrenia. Bolded figures indicate values associated with
recommended cutoff points.

symptoms than untreated patients or individuals. Although the
WERCAP Screen was intended to elicit chronic or lifetime symptoms, it is plausible that individuals who have been psychiatrically

Frontiers in Psychiatry | www.frontiersin.org

stable could nevertheless underestimate their symptom severity.
Thus, we believe that a score of 13 may be too conservative a cutoff
in community settings, and would likely identify individuals
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without any significant psychopathology. Psychotic-like experiences are relatively common, especially at younger ages, and
most with such experiences never develop psychotic disorders
(93–96). For screening individuals with psychotic disorders in an
unmedicated population, a higher cutoff score would, therefore,
likely be more specific.
Contrary to our hypothesis, the Stress Screen score and number of common substances (tobacco, coffee, other caffeinated
beverages, alcohol, and cannabis) were not significant predictors
of diagnostic category, suggesting that these characteristics are
non-specific to psychiatric diagnoses. This is not entirely surprising, as multiple other psychiatric disorders, including depression,
anxiety, and externalizing disorders have been associated with
psychosocial stress (97, 98) and substance use (99, 100). With
regard to substance-use assessment, it should be noted that the
Substance Screen by default captures current substance-use frequency. It is, thus, conceivable that lifetime exposure to specific
substances would be more predictive of BPD or SCZ than recent
exposure. Diagnoses of SUDs frequently precede onset of SCZ
and BPD (24). Certain substances are specifically associated
with symptom onset or exacerbation. For example, cannabis use
increases the risk of subsequent mania (101) and psychosis (102).
Substance use has also been associated with earlier onset of mania
(36, 103) and psychosis (104). A meta-analysis found that cannabis and unspecified substance use significantly increased age of
onset of psychosis by 2.70 and 2.00 years, respectively, compared
to non-substance-using controls (105). Substance abuse has also
been reported to predict conversion to psychosis in a population
at high clinical risk (106).
Our study provides an initial investigation of the utility of
three recently developed screening instruments in identifying
SCZ and BPD. Accurately diagnosing these medical disorders
would, however, continue to require clinical or structured
assessments, as established diagnostic criteria are complex, often
involving multiple symptom categories (e.g., positive, negative,
and disorganization symptoms for SCZ), specific duration of
symptoms, and diagnostic exclusions (107, 108); thus, screening questionnaires should not be expected to be sufficient for

diagnosis. Nevertheless, they can be useful for identifying
individuals who may require further assessment. A limitation to
our study is that it was conducted using a moderately small-sized
sample. Furthermore, the study population was not representative of the community, where a wider range of psychopathologies
exist which could make identifying bipolar or psychotic disorders
more difficult. Thus, larger studies in diverse settings would be
needed to adequately test the psychometric properties of these
instruments. Nonetheless, this study demonstrates the potential
of the WERC Screen as a screening tool for BPD and SCZ, especially in areas with limited access to a trained psychiatrist, or in
settings where conducting a detailed interview is not feasible.
Well-validated, self-report instruments could play an increasing
role in mental health care in the future. There are relatively few
mental health providers, with primary care providers providing
a greater proportion of mental health care while faced with
increasing time constraints (109). Screening for mental illness
could also be useful in schools to identify individuals early
when intervention could diminish the burden on the illness
and improve functioning. Developing and validating improved
screening tools for various aspects of psychopathology are,
therefore, highly recommended.

AUTHOR CONTRIBUTIONS
DM designed and supervised the study. CH and DG performed
analyses. CH, DG, and DM wrote the paper. All authors contributed to discussion of results and contributed to the manuscript
at all stages.

FUNDING
The research was supported by NIH grant R01 MH104414, as well
as the Taylor Family Institute and Center for Brain Research on
Mood Disorders at the Department of Psychiatry, Washington
University in St. Louis. Dr. DM has previously received grants
from the NIMH, NARSAD, the McDonnell Center for Systems
Neuroscience, the Taylor Family Institute, and Eli Lilly.

REFERENCES

6. Altamura AC, Dell’Osso B, Berlin HA, Buoli M, Bassetti R, Mundo E.
Duration of untreated illness and suicide in bipolar disorder: a naturalistic
study. Eur Arch Psychiatry Clin Neurosci (2010) 260(5):385–91. doi:10.1007/
s00406-009-0085-2
7. Goldberg JF, Ernst CL. Features associated with the delayed initiation of
mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry (2002)
63(11):985–91. doi:10.4088/JCP.v63n1105
8. Altamura AC, Buoli M, Caldiroli A, Caron L, Cumerlato Melter C, Dobrea
C, et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in
bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord
(2015) 182:70–5. doi:10.1016/j.jad.2015.04.024
9. Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression
following initial identification of bipolar disorder: a common and costly misdiagnosis. J Clin Psychiatry (2008) 69(5):749–58. doi:10.4088/JCP.v69n0508
10. Keck PE Jr, Kessler RC, Ross R. Clinical and economic effects of unrecognized
or inadequately treated bipolar disorder. J Psychiatr Pract (2008) 14(Suppl
2):31–8. doi:10.1097/01.pra.0000320124.91799.2a
11. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in
prevention of affective episodes. A comparison in recurrent affective
illness. Arch Gen Psychiatry (1973) 29(3):420–5. doi:10.1001/archpsyc.1973.
04200030104017

1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE,
et al. Global burden of disease attributable to mental and substance use
disorders: findings from the Global Burden of Disease Study 2010. Lancet
(2013) 382(9904):1575–86. doi:10.1016/S0140-6736(13)61611-6
2. Penttila M, Jaaskelainen E, Hirvonen N, Isohanni M, Miettunen J. Duration
of untreated psychosis as predictor of long-term outcome in schizophrenia:
systematic review and meta-analysis. Br J Psychiatry (2014) 205(2):88–94.
doi:10.1192/bjp.bp.113.127753
3. Cechnicki A, Cichocki L, Kalisz A, Bladzinski P, Adamczyk P, Franczyk-Glita
J. Duration of untreated psychosis (DUP) and the course of schizophrenia in
a 20-year follow-up study. Psychiatry Res (2014) 219(3):420–5. doi:10.1016/j.
psychres.2014.05.046
4. Ran MS, Weng X, Chan CL, Chen EY, Tang CP, Lin FR, et al. Different
outcomes of never-treated and treated patients with schizophrenia: 14-year
follow-up study in rural China. Br J Psychiatry (2015) 207(6):495–500.
doi:10.1192/bjp.bp.114.157685
5. Cohen A, Patel V, Thara R, Gureje O. Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull (2008)
34(2):229–44. doi:10.1093/schbul/sbm105

Frontiers in Psychiatry | www.frontiersin.org

10

August 2016 | Volume 7 | Article 149

Hsieh et al.

Utility of WERC Self-Report Questionnaires

12. Drancourt N, Etain B, Lajnef M, Henry C, Raust A, Cochet B, et al.
Duration of untreated bipolar disorder: missed opportunities on the long
road to optimal treatment. Acta Psychiatr Scand (2013) 127(2):136–44.
doi:10.1111/j.1600-0447.2012.01917.x
13. Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman SelfRating Mania Scale. Biol Psychiatry (1997) 42(10):948–55. doi:10.1016/
S0006-3223(96)00548-3
14. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 133:429–35. doi:10.1192/
bjp.133.5.429
15. Nassir Ghaemi S, Miller CJ, Berv DA, Klugman J, Rosenquist KJ, Pies RW.
Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect
Disord (2005) 84(2–3):273–7. doi:10.1016/S0165-0327(03)00196-4
16. Miller CJ, Johnson SL, Kwapil TR, Carver CS. Three studies on self-report
scales to detect bipolar disorder. J Affect Disord (2011) 128(3):199–210.
doi:10.1016/j.jad.2010.07.012
17. Zimmerman M, Galione JN, Ruggero CJ, Chelminski I, Dalrymple K,
Young D. Are screening scales for bipolar disorder good enough to be used
in clinical practice? Compr Psychiatry (2011) 52(6):600–6. doi:10.1016/j.
comppsych.2011.01.004
18. Zimmerman M, Galione JN, Chelminski I, Young D, Ruggero CJ. Performance
of the Bipolar Spectrum Diagnostic Scale in psychiatric outpatients. Bipolar
Disord (2010) 12(5):528–38. doi:10.1111/j.1399-5618.2010.00840.x
19. Boonstra N, Wunderink L, Sytema S, Wiersma D. Improving detection of first-episode psychosis by mental health-care services using a
self-report questionnaire. Early Interv Psychiatry (2009) 3(4):289–95.
doi:10.1111/j.1751-7893.2009.00147.x
20. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa
City: University of Iowa (1984).
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr Bull (1987) 13(2):261–76. doi:10.1093/
schbul/13.2.261
22. Mamah D, Owoso A, Sheffield JM, Bayer C. The WERCAP screen and the
WERC stress screen: psychometrics of self-rated instruments for assessing
bipolar and psychotic disorder risk and perceived stress burden. Compr
Psychiatry (2014) 55(7):1757–71. doi:10.1016/j.comppsych.2014.07.004
23. Holtzman CW, Trotman HD, Goulding SM, Ryan AT, Macdonald
AN, Shapiro DI, et al. Stress and neurodevelopmental processes in the
emergence of psychosis. Neuroscience (2013) 249:172–91. doi:10.1016/j.
neuroscience.2012.12.017
24. Andersen SM, Randers A, Jensen CM, Bisgaard C, Steinhausen HC. Preceding
diagnoses to young adult bipolar disorder and schizophrenia in a nationwide
study. BMC Psychiatry (2013) 13:343. doi:10.1186/1471-244X-13-343
25. Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause
psychosis? Systematic review and meta-analysis. Lancet Psychiatry (2015)
2(8):718–25. doi:10.1016/S2215-0366(15)00152-2
26. Myles N, Newall HD, Curtis J, Nielssen O, Shiers D, Large M. Tobacco use
before, at, and after first-episode psychosis: a systematic meta-analysis. J Clin
Psychiatry (2012) 73(4):468–75. doi:10.4088/JCP.11r07222
27. Agrawal A, Nurnberger JI Jr, Lynskey MT, Bipolar Genome S. Cannabis
involvement in individuals with bipolar disorder. Psychiatry Res (2011)
185(3):459–61. doi:10.1016/j.psychres.2010.07.007
28. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke
M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet (2007) 370(9584):319–28. doi:10.1016/
S0140-6736(07)61162-3
29. Leeson VC, Harrison I, Ron MA, Barnes TR, Joyce EM. The effect of cannabis
use and cognitive reserve on age at onset and psychosis outcomes in first-
episode schizophrenia. Schizophr Bull (2012) 38(4):873–80. doi:10.1093/
schbul/sbq153
30. Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, et al.
Marijuana use in the immediate 5-year premorbid period is associated with
increased risk of onset of schizophrenia and related psychotic disorders.
Schizophr Res (2016) 171(1–3):62–7. doi:10.1016/j.schres.2016.01.015
31. Compton MT, Kelley ME, Ramsay CE, Pringle M, Goulding SM,
Esterberg ML, et al. Association of pre-onset cannabis, alcohol, and tobacco
use with age at onset of prodrome and age at onset of psychosis in first-
episode patients. Am J Psychiatry (2009) 166(11):1251–7. doi:10.1176/appi.
ajp.2009.09030311

Frontiers in Psychiatry | www.frontiersin.org

32. Helle S, Ringen PA, Melle I, Larsen TK, Gjestad R, Johnsen E, et al. Cannabis
use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119). Schizophr Res (2016)
170(1):217–21. doi:10.1016/j.schres.2015.11.027
33. Stefanis NC, Dragovic M, Power BD, Jablensky A, Castle D, Morgan VA.
The effect of drug use on the age at onset of psychotic disorders in an
Australian cohort. Schizophr Res (2014) 156(2–3):211–6. doi:10.1016/j.
schres.2014.04.003
34. Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N, Kahn RS,
et al. Age at onset of non-affective psychosis in relation to cannabis use,
other drug use and gender. Psychol Med (2012) 42(9):1903–11. doi:10.1017/
S0033291712000062
35. Tosato S, Lasalvia A, Bonetto C, Mazzoncini R, Cristofalo D, De Santi K,
et al. The impact of cannabis use on age of onset and clinical characteristics
in first-episode psychotic patients. Data from the Psychosis Incident Cohort
Outcome Study (PICOS). J Psychiatr Res (2013) 47(4):438–44. doi:10.1016/j.
jpsychires.2012.11.009
36. Lagerberg TV, Sundet K, Aminoff SR, Berg AO, Ringen PA, Andreassen OA,
et al. Excessive cannabis use is associated with earlier age at onset in
bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2011) 261(6):397–405.
doi:10.1007/s00406-011-0188-4
37. De Hert M, Wampers M, Jendricko T, Franic T, Vidovic D, De Vriendt N,
et al. Effects of cannabis use on age at onset in schizophrenia and bipolar
disorder. Schizophr Res (2011) 126(1–3):270–6. doi:10.1016/j.schres.2010.
07.003
38. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis
use and mania symptoms: a systematic review and meta-analysis. J Affect
Disord (2015) 171:39–47. doi:10.1016/j.jad.2014.09.016
39. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S,
Allebeck P. Prognosis of schizophrenia in persons with and without a
history of cannabis use. Psychol Med (2014) 44(12):2513–21. doi:10.1017/
S0033291714000191
40. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis
relapse in recent-onset psychosis. Prospective study. Br J Psychiatry (2006)
189:137–43. doi:10.1192/bjp.bp.105.014308
41. Seddon JL, Birchwood M, Copello A, Everard L, Jones PB, Fowler D, et al.
Cannabis use is associated with increased psychotic symptoms and poorer
psychosocial functioning in first-episode psychosis: a report from the UK
national EDEN study. Schizophr Bull (2016) 42(3):619–25. doi:10.1093/
schbul/sbv154
42. van der Meer FJ, Velthorst E, Genetic R. Outcome of psychosis I. Course of
cannabis use and clinical outcome in patients with non-affective psychosis:
a 3-year follow-up study. Psychol Med (2015) 45(9):1977–88. doi:10.1017/
S0033291714003092
43. Clausen L, Hjorthoj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M,
et al. Change in cannabis use, clinical symptoms and social functioning
among patients with first-episode psychosis: a 5-year follow-up study of
patients in the OPUS trial. Psychol Med (2014) 44(1):117–26. doi:10.1017/
S0033291713000433
44. Stone JM, Fisher HL, Major B, Chisholm B, Woolley J, Lawrence J, et al.
Cannabis use and first-episode psychosis: relationship with manic and
psychotic symptoms, and with age at presentation. Psychol Med (2014)
44(3):499–506. doi:10.1017/S0033291713000883
45. Myles H, Myles N, Large M. Cannabis use in first episode psychosis:
meta-
analysis of prevalence, and the time course of initiation and
continued use. Aust N Z J Psychiatry (2016) 50(3):208–19. doi:10.1177/
0004867415599846
46. Patel R, Wilson R, Jackson R, Ball M, Shetty H, Broadbent M, et al. Association
of cannabis use with hospital admission and antipsychotic treatment
failure in first episode psychosis: an observational study. BMJ open (2016)
6(3):e009888. doi:10.1136/bmjopen-2015-009888
47. Gonzalez-Ortega I, Alberich S, Echeburua E, Aizpuru F, Millan E, Vieta E,
et al. Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. PLoS One (2015)
10(4):e0123707. doi:10.1371/journal.pone.0123707
48. Zorrilla I, Aguado J, Haro JM, Barbeito S, Lopez Zurbano S, Ortiz A, et al.
Cannabis and bipolar disorder: does quitting cannabis use during manic/
mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand
(2015) 131(2):100–10. doi:10.1111/acps.12366

11

August 2016 | Volume 7 | Article 149

Hsieh et al.

Utility of WERC Self-Report Questionnaires

49. Kim SW, Dodd S, Berk L, Kulkarni J, de Castella A, Fitzgerald PB, et al.
Impact of cannabis use on long-term remission in bipolar I and schizoaffective disorder. Psychiatry Investig (2015) 12(3):349–55. doi:10.4306/
pi.2015.12.3.349
50. Kotov R, Guey LT, Bromet EJ, Schwartz JE. Smoking in schizophrenia:
diagnostic specificity, symptom correlates, and illness severity. Schizophr Bull
(2010) 36(1):173–81. doi:10.1093/schbul/sbn066
51. Vanable PA, Carey MP, Carey KB, Maisto SA. Smoking among psychiatric
outpatients: relationship to substance use, diagnosis, and illness severity.
Psychol Addict Behav (2003) 17(4):259–65. doi:10.1037/0893-164X.17.4.259
52. Berk M, Ng F, Wang WV, Tohen M, Lubman DI, Vieta E, et al. Going up
in smoke: tobacco smoking is associated with worse treatment outcomes in
mania. J Affect Disord (2008) 110(1–2):126–34. doi:10.1016/j.jad.2008.01.018
53. Wang HR, Woo YS, Bahk WM. Caffeine-induced psychiatric manifestations:
a review. Int Clin Psychopharmacol (2015) 30(4):179–82. doi:10.1097/
YIC.0000000000000076
54. Rizkallah E, Belanger M, Stavro K, Dussault M, Pampoulova T, Chiasson JP,
et al. Could the use of energy drinks induce manic or depressive relapse
among abstinent substance use disorder patients with comorbid bipolar spectrum disorder? Bipolar Disord (2011) 13(5–6):578–80. doi:10.1111/j.13995618.2011.00951.x
55. Hughes K, Lowey H, Quigg Z, Bellis MA. Relationships between adverse
childhood experiences and adult mental well-being: results from an English
national household survey. BMC Public Health (2016) 16:222. doi:10.1186/
s12889-016-2906-3
56. Schilling EA, Aseltine RH Jr, Gore S. Adverse childhood experiences and
mental health in young adults: a longitudinal survey. BMC Public Health
(2007) 7:30. doi:10.1186/1471-2458-7-30
57. Bechdolf A, Thompson A, Nelson B, Cotton S, Simmons MB, Amminger GP,
et al. Experience of trauma and conversion to psychosis in an ultra-highrisk (prodromal) group. Acta Psychiatr Scand (2010) 121(5):377–84.
doi:10.1111/j.1600-0447.2010.01542.x
58. Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al.
Childhood adversities increase the risk of psychosis: a meta-analysis of
patient-control, prospective- and cross-sectional cohort studies. Schizophr
Bull (2012) 38(4):661–71. doi:10.1093/schbul/sbs050
59. Trauelsen AM, Bendall S, Jansen JE, Nielsen HG, Pedersen MB, Trier CH,
et al. Childhood adversity specificity and dose-response effect in nonaffective first-episode psychosis. Schizophr Res (2015) 165(1):52–9.

doi:10.1016/j.schres.2015.03.014
60. Agnew-Blais J, Danese A. Childhood maltreatment and unfavourable
clinical outcomes in bipolar disorder: a systematic review and meta-analysis.
Lancet Psychiatry (2016) 3(4):342–9. doi:10.1016/S2215-0366(15)00544-1
61. Dienes KA, Hammen C, Henry RM, Cohen AN, Daley SE. The stress sensitization hypothesis: understanding the course of bipolar disorder. J Affect
Disord (2006) 95(1–3):43–9. doi:10.1016/j.jad.2006.04.009
62. Myin-Germeys I, Peeters F, Havermans R, Nicolson NA, DeVries MW,
Delespaul P, et al. Emotional reactivity to daily life stress in psychosis and
affective disorder: an experience sampling study. Acta Psychiatr Scand (2003)
107(2):124–31. doi:10.1034/j.1600-0447.2003.02025.x
63. McLaughlin KA, Conron KJ, Koenen KC, Gilman SE. Childhood adversity,
adult stressful life events, and risk of past-year psychiatric disorder: a test of
the stress sensitization hypothesis in a population-based sample of adults.
Psychol Med (2010) 40(10):1647–58. doi:10.1017/S0033291709992121
64. Beards S, Gayer-Anderson C, Borges S, Dewey ME, Fisher HL, Morgan C.
Life events and psychosis: a review and meta-analysis. Schizophr Bull (2013)
39(4):740–7. doi:10.1093/schbul/sbt065
65. Kemner SM, van Haren NE, Bootsman F, Eijkemans MJ, Vonk R, van der
Schot AC, et al. The influence of life events on first and recurrent admissions in bipolar disorder. Int J Bipolar Disord (2015) 3:6. doi:10.1186/
s40345-015-0022-4
66. Gilman SE, Ni MY, Dunn EC, Breslau J, McLaughlin KA, Smoller JW, et al.
Contributions of the social environment to first-onset and recurrent mania.
Mol Psychiatry (2015) 20(3):329–36. doi:10.1038/mp.2014.36
67. Etain B, Aas M, Andreassen OA, Lorentzen S, Dieset I, Gard S, et al.
Childhood trauma is associated with severe clinical characteristics of bipolar
disorders. J Clin Psychiatry (2013) 74(10):991–8. doi:10.4088/JCP.13m08353
68. Freeman D, Emsley R, Dunn G, Fowler D, Bebbington P, Kuipers E, et al.
The stress of the street for patients with persecutory delusions: a test of the

Frontiers in Psychiatry | www.frontiersin.org

69.

70.
71.
72.
73.
74.
75.
76.
77.
78.

79.

80.
81.
82.

83.

84.

85.

86.
87.
88.

12

symptomatic and psychological effects of going outside into a busy urban
area. Schizophr Bull (2015) 41(4):971–9. doi:10.1093/schbul/sbu173
Simhandl C, Radua J, Konig B, Amann BL. The prevalence and effect
of life events in 222 bipolar I and II patients: a prospective, naturalistic
4 year follow-up study. J Affect Disord (2015) 170:166–71. doi:10.1016/j.
jad.2014.08.043
Taylor PJ, Hutton P, Wood L. Are people at risk of psychosis also at risk of
suicide and self-harm? A systematic review and meta-analysis. Psychol Med
(2015) 45(5):911–26. doi:10.1017/S0033291714002074
Kooyman I, Dean K, Harvey S, Walsh E. Outcomes of public concern in
schizophrenia. Br J Psychiatry Suppl (2007) 50:s29–36. doi:10.1192/bjp.
191.50.s29
Millier A, Schmidt U, Angermeyer MC, Chauhan D, Murthy V, Toumi M,
et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res
(2014) 54:85–93. doi:10.1016/j.jpsychires.2014.03.021
Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of
depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res (2007) 90(1–3):186–97. doi:10.1016/j.schres.2006.09.027
Fuller-Thomson E, Hollister B. Schizophrenia and suicide attempts: findings
from a representative community-based Canadian sample. Schizophr Res
Treatment (2016) 2016:3165243. doi:10.1155/2016/3165243
Bland RC, Newman SC, Orn H. Schizophrenia: lifetime co-morbidity in a
community sample. Acta Psychiatr Scand (1987) 75(4):383–91. doi:10.1111/
j.1600-0447.1987.tb02806.x
Hor K, Taylor M. Suicide and schizophrenia: a systematic review of
rates and risk factors. J Psychopharmacol (2010) 24(4 Suppl):81–90.
doi:10.1177/1359786810385490
Swann AC. The strong relationship between bipolar and substance-use disorder.
Ann N Y Acad Sci (2010) 1187:276–93. doi:10.1111/j.1749-6632.2009.05146.x
Gibson LE, Anglin DM, Klugman JT, Reeves LE, Fineberg AM, Maxwell SD,
et al. Stress sensitivity mediates the relationship between traumatic life events
and attenuated positive psychotic symptoms differentially by gender in a
college population sample. J Psychiatr Res (2014) 53:111–8. doi:10.1016/j.
jpsychires.2014.02.020
Collip D, Wigman JT, Myin-Germeys I, Jacobs N, Derom C, Thiery E, et al.
From epidemiology to daily life: linking daily life stress reactivity to persistence of psychotic experiences in a longitudinal general population study.
PLoS One (2013) 8(4):e62688. doi:10.1371/journal.pone.0062688
Myin-Germeys I, van Os J, Schwartz JE, Stone AA, Delespaul PA. Emotional
reactivity to daily life stress in psychosis. Arch Gen Psychiatry (2001)
58(12):1137–44. doi:10.1001/archpsyc.58.12.1137
Myin-Germeys I, van Os J. Stress-reactivity in psychosis: evidence for
an affective pathway to psychosis. Clin Psychol Rev (2007) 27(4):409–24.
doi:10.1016/j.cpr.2006.09.005
Wieck A, Grassi-Oliveira R, do Prado CH, Rizzo LB, de Oliveira AS,
Kommers-Molina J, et al. Pro-inflammatory cytokines and soluble receptors
in response to acute psychosocial stress: differential reactivity in bipolar
disorder. Neurosci Lett (2014) 580:17–21. doi:10.1016/j.neulet.2014.07.040
Luutonen S, Tikka M, Karlsson H, Salokangas RK. Childhood trauma and
distress experiences associate with psychotic symptoms in patients attending primary and psychiatric outpatient care. Results of the RADEP study.
Eur Psychiatry (2013) 28(3):154–60. doi:10.1016/j.eurpsy.2011.11.005
Collip D, Nicolson NA, Lardinois M, Lataster T, van Os J, Myin-Germeys I,
et al. Daily cortisol, stress reactivity and psychotic experiences in individuals
at above average genetic risk for psychosis. Psychol Med (2011) 41(11):
2305–15. doi:10.1017/S0033291711000602
Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B,
et al. The HPA axis in bipolar disorder: systematic review and meta-analysis.
Psychoneuroendocrinology (2016) 63:327–42. doi:10.1016/j.psyneuen.2015.
10.014
Girshkin L, Matheson SL, Shepherd AM, Green MJ. Morning cortisol levels in
schizophrenia and bipolar disorder: a meta-analysis. Psychoneuroendocrinology
(2014) 49:187–206. doi:10.1016/j.psyneuen.2014.07.013
Holtzman CW, Shapiro DI, Trotman HD, Walker EF. Stress and the
prodromal phase of psychosis. Curr Pharm Des (2012) 18(4):527–33.
doi:10.2174/138161212799316280
Tessner KD, Mittal V, Walker EF. Longitudinal study of stressful life events
and daily stressors among adolescents at high risk for psychotic disorders.
Schizophr Bull (2011) 37(2):432–41. doi:10.1093/schbul/sbp087

August 2016 | Volume 7 | Article 149

Hsieh et al.

Utility of WERC Self-Report Questionnaires

89. Brietzke E, Mansur RB, Soczynska J, Powell AM, McIntyre RS. A theoretical
framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2012)
39(1):1–8. doi:10.1016/j.pnpbp.2012.05.004
90. Horesh N, Apter A, Zalsman G. Timing, quantity and quality of stressful
life events in childhood and preceding the first episode of bipolar disorder.
J Affect Disord (2011) 134(1–3):434–7. doi:10.1016/j.jad.2011.05.034
91. Streit F, Memic A, Hasandedic L, Rietschel L, Frank J, Lang M, et al.
Perceived stress and hair cortisol: differences in bipolar disorder and
schizophrenia. Psychoneuroendocrinology (2016) 69:26–34. doi:10.1016/j.
psyneuen.2016.03.010
92. Corcoran C, Walker E, Huot R, Mittal V, Tessner K, Kestler L, et al. The
stress cascade and schizophrenia: etiology and onset. Schizophr Bull (2003)
29(4):671–92. doi:10.1093/oxfordjournals.schbul.a007038
93. Nelson B, Fusar-Poli P, Yung AR. Can we detect psychotic-like experiences in the general population? Curr Pharm Des (2012) 18(4):376–85.
doi:10.2174/138161212799316136
94. Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM.
Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia.
Aust N Z J Psychiatry (2009) 43(2):118–28. doi:10.1080/00048670802607188
95. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for
a psychosis proneness-persistence-impairment model of psychotic disorder.
Psychol Med (2009) 39(2):179–95. doi:10.1017/S0033291708003814
96. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H.
Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry (2000)
57(11):1053–8. doi:10.1001/archpsyc.57.11.1053
97. Newman SC, Bland RC. Life events and the 1-year prevalence of major
depressive episode, generalized anxiety disorder, and panic disorder in a
community sample. Compr Psychiatry (1994) 35(1):76–82. doi:10.1016/
0010-440X(94)90173-2
98. Stroud CB, Davila J, Moyer A. The relationship between stress and depression
in first onsets versus recurrences: a meta-analytic review. J Abnorm Psychol
(2008) 117(1):206–13. doi:10.1037/0021-843X.117.1.206
99. Kenneson A, Funderburk JS, Maisto SA. Substance use disorders increase
the odds of subsequent mood disorders. Drug Alcohol Depend (2013)
133(2):338–43. doi:10.1016/j.drugalcdep.2013.06.011
100. Alegria AA, Hasin DS, Nunes EV, Liu SM, Davies C, Grant BF, et al. Comor
bidity of generalized anxiety disorder and substance use disorders: results

Frontiers in Psychiatry | www.frontiersin.org

101.
102.
103.

104.
105.
106.

107.
108.
109.

from the National Epidemiologic Survey on Alcohol and Related Conditions.
J Clin Psychiatry (2010) 71(9):1187–95. doi:10.4088/JCP.09m05328gry
Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use
and expression of mania in the general population. J Affect Disord (2006)
95(1–3):103–10. doi:10.1016/j.jad.2006.05.002
Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for
psychosis: systematic review. J Psychopharmacol (2005) 19(2):187–94.
doi:10.1177/0269881105049040
Leite RT, Nogueira Sde O, do Nascimento JP, de Lima LS, da Nobrega TB,
Virginio Mda S, et al. The use of cannabis as a predictor of early onset of
bipolar disorder and suicide attempts. Neural Plast (2015) 2015:434127.
doi:10.1155/2015/434127
Tucker P. Substance misuse and early psychosis. Australas Psychiatry (2009)
17(4):291–4. doi:10.1080/10398560802657314
Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and
earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry
(2011) 68(6):555–61. doi:10.1001/archgenpsychiatry.2011.5
Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E,
et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry (2008) 65(1):28–37.
doi:10.1001/archgenpsychiatry.2007.3
Parker G, Fletcher K. Differentiating bipolar I and II disorders and the likely
contribution of DSM-5 classification to their cleavage. J Affect Disord (2014)
15(2–154):57–64. doi:10.1016/j.jad.2013.10.006
Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, et al.
Definition and description of schizophrenia in the DSM-5. Schizophr Res
(2013) 150(1):3–10. doi:10.1016/j.schres.2013.05.028
Olfson M, Kroenke K, Wang S, Blanco C. Trends in office-based mental
health care provided by psychiatrists and primary care physicians. J Clin
Psychiatry (2014) 75(3):247–53. doi:10.4088/JCP.13m08834

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2016 Hsieh, Godwin and Mamah. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.

13

August 2016 | Volume 7 | Article 149

